95216-61-8

Upstream product

• 24067-17-2 4-nitrophenylboronic acid 
• 1516-60-5 4-nitrophenyl azide 
• 5894-65-5 N-t-butylbenzamide 
• 1404220-24-1 N-tert-butyl-2-(4-nitrophenylamino)benzamide 
• 28144-70-9 anthranilic acid amide 
• 586-78-7 para-nitrophenyl bromide 
• 7221-31-0 SM⁽⁰¹⁷⁾R₀₀₁₉₀₈ 

Downstream Products

• 70368-48-8 2-Isopropyl-1-(4-nitro-phenyl)-1H-quinazolin-4-one 
• 95216-43-6 2-cyclobutyl-1-(4-nitrophenyl)-4(1H)-quinazolinone 
• 1021142-36-8 2-(4-aminophenylamino)benzamide 
• 1382354-43-9 tert-butyl 4-((4-2-carbamoylphenylaminophenyl)carbamoyl)piperidine-1-carboxylate 
• 1382353-99-2 2-(4-acetamidophenylamino)benzamide 
• 1382354-00-8 2-(4-isobutyramidophenylamino)benzamide 
• 1382354-01-9 2-(4-cyclohexanecarboxamidophenylamino)benzamide 
• 95216-44-7 1-(4-aminophenyl)-2-isopropyl-4(1H)-quinazolinone 
• 95216-41-4 2-Cyclopropyl-1-(4-nitro-phenyl)-1H-quinazolin-4-one 

Relevant academic research and scientific papers

Rhodium-catalyzed direct C-H amination of benzamides with aryl azides: A synthetic route to diarylamines

No muss, no fuss: A rhodium-catalyzed direct intermolecular C-H amination of benzamides and ketoximes using aryl azides as the amine source has been developed. The reaction exhibits a broad substrate scope with excellent functional-group tolerance, requires no external oxidants, releases N 2 as the only by-product, and produces diarylamines in high yields. Copyright

Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors

Selective inhibitors of human sirtuin 2 (SIRT2), a deacetylase, are candidate therapeutic agents for neurodegenerative diseases such as Parkinson's disease and Huntington's disease as well as potential tools for elucidating the biological functions of SIRT2. On the basis of homology models of SIRT1 and SIRT2, we designed and prepared a series of 2-anilinobenzamide analogues. Enzyme assays using recombinant SIRT1 and SIRT2 revealed that 3'-phenethyloxy-2- anilinobenzamide analogues such as 33a and 33i are potent and selective SIRT2 inhibitors, showing more than 3.5-fold greater SIRT2-inhibitory activity and more than 35-fold greater SIRT2-selectivity compared with AGK2 (3), a previously reported SIRT2-selective inhibitor. Compound 33a also induced a dose-dependent selective increase of α-tubulin acetylation in human colon cancer HCT116 cells, indicating selective inhibition of SIRT2 in the cells. These 3'-phenethyloxy-2-anilinobenzamide derivatives represent an entry into a new class of SIRT2-selective inhibitors.

Studies on 4(1H)-quinazolinones. 5. Synthesis and antiinflammatory activity of 4(1H)-quinazolinone derivatives

A number of new 4(1H)-quinazolinones were synthesized and evaluated in the carrageenin-induced paw edema test. Most of the compounds were obtained by the cyclization of the appropriately substituted anthranilamides with acid chlorides, followed by further chemical transformation. Structure-activity data suggest that 2-isopropyl-1-phenyl-, 2-cyclopropyl-1-phenyl-, and 1-isopropyl-2-phenyl-4(1H)-quinazolinones afford optimal potency and the presence of a halogen atom is preferred for activity. Adrenalectomy does not affect the antiinflammatory test results. The best result taking into account both efficacy and side effects was displayed by 1-isoproyl-(2-fluorophenyl)-4(1H)-quinazolinone.